Literature DB >> 32369162

Free and Glucuronide Urine Cannabinoids after Controlled Smoked, Vaporized and Oral Cannabis Administration in Frequent and Occasional Cannabis Users.

Marilyn A Huestis1,2, Cristina Sempio1,3, Matthew N Newmeyer1,4, Maria Andersson1,5, Allan J Barnes1,6, Osama A Abulseoud7, Benjamin C Blount8, Jennifer Schroeder9, Michael L Smith10.   

Abstract

Total urinary 11-nor-9-carboxy-tetrahydrocannabinol (THCCOOH) concentrations are generally reported following cannabis administration. Few data are available for glucuronide and minor cannabinoid metabolite concentrations. All urine specimens from 11 frequent and 9 occasional cannabis users were analyzed for 11 cannabinoids for ~85 h by liquid chromatography with tandem mass spectrometry following controlled smoked, vaporized or oral 50.6 mg Δ9-tetrahydrocannabinol (THC) in a randomized, placebo-controlled, within-subject dosing design. No cannabidiol, cannabinol, cannabigerol, tetrahydrocannabivarin (THCV), THC, 11-OH-THC and Δ9-tetrahydrocannabinolic acid were detected in urine. Median THCCOOH-glucuronide maximum concentrations (Cmax) following smoked, vaporized and oral routes were 68.0, 26.7 and 360 μg/L for occasional and 378, 248 and 485 μg/L for frequent users, respectively. Median time to specific gravity-normalized Cmax (Tmax) was 5.1-7.9 h for all routes and all users. Median Cmax for THCCOOH, THC-glucuronide and 11-nor-9-carboxy-Δ9-THCV (THCVCOOH) were <7.5% of THCCOOH-glucuronide Cmax concentrations. Only THC-glucuronide mean Tmax differed between routes and groups, and was often present only in occasional users' first urine void. Multiple THCCOOH-glucuronide and THCCOOH peaks were observed. We also evaluated these urinary data with published models for determining recency of cannabis use. These urinary cannabinoid marker concentrations from occasional and frequent cannabis users following three routes of administration provide a scientific database to assess single urine concentrations in cannabis monitoring programs. New target analytes (CBD, CBN, CBG, THCV and phase II metabolites) were not found in urine. The results are important to officials in drug treatment, workplace and criminal justice drug monitoring programs, as well as policy makers with responsibility for cannabis regulations. Published by Oxford University Press 2020.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32369162      PMCID: PMC7673603          DOI: 10.1093/jat/bkaa046

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  21 in total

1.  Simultaneous quantification of free and glucuronidated cannabinoids in human urine by liquid chromatography tandem mass spectrometry.

Authors:  Karl B Scheidweiler; Nathalie A Desrosiers; Marilyn A Huestis
Journal:  Clin Chim Acta       Date:  2012-07-06       Impact factor: 3.786

Review 2.  The dark cloud of recreational drugs and vaping.

Authors:  M S Blundell; P I Dargan; D M Wood
Journal:  QJM       Date:  2018-03-01

3.  Detection times of marijuana metabolites in urine by immunoassay and GC-MS.

Authors:  M A Huestis; J M Mitchell; E J Cone
Journal:  J Anal Toxicol       Date:  1995-10       Impact factor: 3.367

4.  Free and Glucuronide Whole Blood Cannabinoids' Pharmacokinetics after Controlled Smoked, Vaporized, and Oral Cannabis Administration in Frequent and Occasional Cannabis Users: Identification of Recent Cannabis Intake.

Authors:  Matthew N Newmeyer; Madeleine J Swortwood; Allan J Barnes; Osama A Abulseoud; Karl B Scheidweiler; Marilyn A Huestis
Journal:  Clin Chem       Date:  2016-10-10       Impact factor: 8.327

5.  Differentiating new cannabis use from residual urinary cannabinoid excretion in chronic, daily cannabis users.

Authors:  Eugene W Schwilke; Rod G Gullberg; William D Darwin; C Nora Chiang; Jean Lud Cadet; David A Gorelick; Harrison G Pope; Marilyn A Huestis
Journal:  Addiction       Date:  2010-12-06       Impact factor: 6.526

6.  Correlation of creatinine- and specific gravity-normalized free and glucuronidated urine cannabinoid concentrations following smoked, vaporized, and oral cannabis in frequent and occasional cannabis users.

Authors:  Marilyn A Huestis; Benjamin C Blount; Daniel F Milan; Matthew N Newmeyer; Jennifer Schroeder; Michael L Smith
Journal:  Drug Test Anal       Date:  2019-03-15       Impact factor: 3.345

Review 7.  Cannabinoid Markers in Biological Fluids and Tissues: Revealing Intake.

Authors:  Marilyn A Huestis; Michael L Smith
Journal:  Trends Mol Med       Date:  2018-02       Impact factor: 11.951

8.  Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users.

Authors:  P Kelly; R T Jones
Journal:  J Anal Toxicol       Date:  1992 Jul-Aug       Impact factor: 3.367

9.  Simultaneous quantification of 11 cannabinoids and metabolites in human urine by liquid chromatography tandem mass spectrometry using WAX-S tips.

Authors:  Maria Andersson; Karl B Scheidweiler; Cristina Sempio; Allan J Barnes; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2016-07-15       Impact factor: 4.142

10.  Urinary elimination of 11-nor-9-carboxy-delta9-tetrahydrocannnabinol in cannabis users during continuously monitored abstinence.

Authors:  Robert S Goodwin; William D Darwin; C Nora Chiang; Ming Shih; Shou-Hua Li; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2008-10       Impact factor: 3.367

View more
  1 in total

1.  Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC) and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration.

Authors:  Dennis J Sholler; Tory R Spindle; Edward J Cone; Elia Goffi; David Kuntz; John M Mitchell; Ruth E Winecker; George E Bigelow; Ronald R Flegel; Ryan Vandrey
Journal:  J Anal Toxicol       Date:  2022-05-20       Impact factor: 3.220

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.